Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Osiris Therapeutics, Inc. (OSIR) since 2014 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Osiris Therapeutics, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1360886.
Total stock buying since 2014: $1,882.
Total stock sales since 2014: $729,410.
Total stock option exercises since 2014: $687,836.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2017 | 0 | $0 | 0 | $0 | 25,000 | $128,400 |
| 2015 | 100 | $1,882 | 22,425 | $415,262 | 66,500 | $421,020 |
| 2014 | 0 | $0 | 20,197 | $314,148 | 20,197 | $138,416 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2017-01 | 0 | $0 | 0 | $0 | 25,000 | $128,400 |
| 2015-11 | 0 | $0 | 0 | $0 | 41,500 | $276,820 |
| 2015-08 | 0 | $0 | 2,425 | $44,183 | 5,000 | $2,000 |
| 2015-06 | 100 | $1,882 | 0 | $0 | 0 | $0 |
| 2015-05 | 0 | $0 | 20,000 | $371,079 | 20,000 | $142,200 |
| 2014-05 | 0 | $0 | 20,197 | $314,148 | 20,197 | $138,416 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2017-01-25 | Dresner David A (Interim President & CEO) | Option Ex | 15,000 | 5.30 | 79,500 |
| 2017-01-23 | Dresner David A (Interim President & CEO) | Option Ex | 5,000 | 5.03 | 25,150 |
| 2017-01-12 | Dresner David A (Interim President & CEO) | Option Ex | 5,000 | 4.75 | 23,750 |
| 2015-11-20 | Debrabandere Lode (President & CEO) | Option Ex | 37,500 | 6.84 | 256,500 |
| 2015-11-19 | Danilkovitch Alla (Chief Scientific Officer) | Option Ex | 4,000 | 5.08 | 20,320 |
| 2015-08-10 | Danilkovitch Alla (Chief Scientific Officer) | Sale | 2,425 | 18.22 | 44,183 |
| 2015-08-10 | Danilkovitch Alla (Chief Scientific Officer) | Option Ex | 5,000 | .40 | 2,000 |
| 2015-06-04 | Law Gregory Ivan (Principal Accounting Officer) | Buy | 100 | 18.83 | 1,882 |
| 2015-05-27 | Jacoby Philip R Jr (Chief Financial Officer) | Sale | 20,000 | 18.55 | 371,079 |
| 2015-05-27 | Jacoby Philip R Jr (Chief Financial Officer) | Option Ex | 20,000 | 7.11 | 142,200 |
| 2014-05-29 | Neumayer Matthew Paul (Principal Accounting Officer) | Sale | 500 | 15.55 | 7,775 |
| 2014-05-29 | Neumayer Matthew Paul (Principal Accounting Officer) | Option Ex | 500 | 6.46 | 3,230 |
| 2014-05-27 | Neumayer Matthew Paul (Principal Accounting Officer) | Sale | 3,750 | 16.10 | 60,375 |
| 2014-05-27 | Neumayer Matthew Paul (Principal Accounting Officer) | Option Ex | 3,750 | 6.92 | 25,950 |
| 2014-05-21 | Jacoby Philip R Jr (Chief Financial Officer) | Sale | 15,947 | 15.43 | 245,998 |
| 2014-05-21 | Jacoby Philip R Jr (Chief Financial Officer) | Option Ex | 15,947 | 6.85 | 109,236 |
Insider trading activities including stock purchases, stock sales, and option exercises of OSIR listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Osiris Therapeutics, Inc. (symbol OSIR, CIK number 1360886) see the Securities and Exchange Commission (SEC) website.